支气管动脉栓塞与血栓塞的保守治疗相比:系统性审查和元分析
Shengxin Fan1, Xiaocheng Cheng1, Xiaohui Wang1
1Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, No.1 Youyi Road, Yuzhong District, Chongqing, 400016, China.
BMC pulmonary medicine
|August 30, 2024
概括
支气管动脉栓塞 (BAE) 比保守治疗血栓塞更有效,减少复发和死亡率. BAE具有很高的临床成功率,并没有很大的并发症,这使其成为首选的干预选择.
科学领域:
- 干预性肺病学 干预性肺病学
- 血管干预 血管干预
- 呼吸系统医学 呼吸系统医学
背景情况:
- 支气管动脉栓塞 (BAE) 是血栓塞的关键治疗方法.
- 缺乏关于BAE有效性和安全性的共识,阻碍了其在血液流管理中的广泛采用.
研究的目的:
- 评估BAE的临床益处,与血栓塞的保守治疗相比.
- 综合关于复发率,临床成功,死亡率和并发症的证据.
主要方法:
- 在PubMed,Embase,ScienceDirect,CochraneLibrary和ClinicalTrials的系统文献搜索到2023年3月.
- 包括随机对照试验 (RCT) 和队列研究,比较BAE与血栓塞的保守治疗.
- 使用几率比率 (OR) 和95%置信区间 (CI) 的聚合数据的元分析.
主要成果:
- 分析了12项涉及1231名患者的研究 (3项RCT,9个队列).
- 与保守治疗相比,BAE显示出更低的血复发率 (26.5%vs34.6%) 和更高的临床成功率 (92.2%vs80.9%).
- BAE显著降低了与血液溶解相关的死亡率 (0.8%与3.2%) 与较低的重大并发症发病率 (0.2%).
结论:
- 在控制血和减少复发方面,BAE优于保守治疗.
- BAE显著降低了与血结相关的死亡率,严重并发症的风险可以忽略不计.
- 这些发现支持BAE作为血液的有效治疗选择.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
142
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
142
01:26COPD: Management Using Bronchodilators and Corticosteroids
188
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
188
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
160
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
160